Strophanthins

01/01/1982 - "It was shown in experiments on rats with experimental ischemic myocardial infarction that strophanthin inhibits free-radical lipid peroxidation, decreases (in mean and little doses) the ectopic activity of the myocardium, eliminates tachyarrhythmias arising in the presence of coronary occlusion, delays the appearance on the ECG of changes characteristic for acute myocardial infarction. "
08/01/1990 - "biomass grown in tissue culture was effective in arresting canine ventricular arrhythmias induced by coronary occlusion, strophanthin and epinephrine, displaying antiarrhythmic effects in aconitine-induced intoxication of rats and substantially elevating the threshold of ventricular fibrillations in cats. "
03/01/1988 - "On six models of arrhythmias of atrial and ventricular types (induced by administration of aconitine, chlorcalcium, chlorbarium, strophanthin, chloroform-adrenaline and by coronary occlusion) it was shown that in rats, cats and rabbits the antiarrhythmic, preventive and relieving activity of brevicarine dichlorhydrate exceeded that of quinidine, novocainamide and lidocaine in power by 3-5 times and in duration by 3-18 times."

01/01/1979 - "[Effect of strophanthin and cytochrome C on myocardial contraction and the incidence of shock and ventricular fibrillation in experimental myocardial infarct]."
08/01/1990 - "biomass grown in tissue culture was effective in arresting canine ventricular arrhythmias induced by coronary occlusion, strophanthin and epinephrine, displaying antiarrhythmic effects in aconitine-induced intoxication of rats and substantially elevating the threshold of ventricular fibrillations in cats. "

01/01/1977 - "In the case of digoxin, digitoxin, and strophanthin the retention is directly related to the normal renal clearance of these cardiac glycosides: Strophanthin has the highest clearance and the most marked prolongation of pharmacological action in renal failure, whereas digitoxin shows the lowest renal clearance and even in uremic patients a total elimination comparable to normal subjects as a result of increased hepatic clearance; digoxin takes an intermediate position. "

01/01/1978 - "[Use of strophanthin in the acute period of myocardial infarct (study of hemodynamics)]."
03/01/1984 - "Strophanthin, when used in the acute period of myocardial infarction, contributes to an increase in the protein decay rate and a decrease in protein synthesis. "
01/01/1982 - "[Inhibition of free-radical lipid peroxidation in myocardial infarct as affected by strophanthin]."
11/01/1980 - "[Effect of strophanthin on central hemodynamics and size of the periinfarction zone in myocardial infarct]."
09/01/1980 - "[Use of strophanthin in the acute period of myocardial infarct]."

10/01/1994 - "The action of the beta-adrenoblocker anaprilline on the pharmacodynamic effects of strophanthin was examined in in vivo experiments during simulated rat heart failure and on isolated frog atrial specimens. "
07/01/1985 - "[Possibilities for the strophanthin pharmacological correction of cardio- and hemodynamic disorders in dogs in the early stage of experimental lung-heart failure]."
08/21/1960 - "[Effect of strophanthin derivatives on cardiac dynamics in heart failure]."
11/25/1957 - "[Strophanthin in congestive heart failure]."
03/01/1990 - "[Treatment of patients with ischemic heart disease in the initial stage of heart failure using strophanthin electrophoresis]."